Skip to main content
Log in

The management of chronic granulomatous disease

  • Immunology/Allergology
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Chronic granulomatous disease (CGD) is a primary immunodeficiency disease which results from absence of the NADPH oxidase in the professional phagocytic cells [13] neutrophils, monocytes, macrophages and eosinophils. Deficiency of this oxidase renders the patient liable to infection by bacteria and fungi, and, as the name of the disease suggests, to chronic granulomatous inflammation. These patients present with a great variety of infections and other complications of their disease, which often tax the clinical and therapeutic skill of the doctors responsible for their care. Collectively we look after, or advise on the management of, over 100 of these subjects, and have developed experience in the diagnosis and management of the infections and other clinical problems they present. We thought that it might be timely to provide guidelines for their management based upon this experience. The numbers of patients are still relatively small, and the clinical presentations very varied, so it is immpossible to provide clear statistical proof of the veracity of this advice. It does, however, reflect the working practise of the physicians caring for many of these patients in Europe.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CGD:

chronic granulomatous disease

NADPH:

nicotinamide adenine dinucleotide phosphate; reduced form

NBT:

nitroblue tetrazolium

References

  1. Cohen MS, Isturiz RE, Malech HL, Root RK, Wilfert CM, Gutmann L, Buckley RH (1981) Fungal infection in chronic granulomatous disease. Am J Med 71:59–62

    PubMed  Google Scholar 

  2. Ezekowitz A (1991) Interferon gamma for chronic granulomatous disease. N Engl J Med 325:1516

    PubMed  Google Scholar 

  3. Ezekowitz RAB, Dinauer MC, Jaffe HS, Orkin SH, Newburger PE (1988) Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N Engl J Med 319:146–151

    PubMed  Google Scholar 

  4. Ezer G, Soothill J (1974) Intracellular bactericidal effects of rifampicin in both normal and chronic granulomatous disease polymorphs. Arch Dis Child 4:463–466

    Google Scholar 

  5. Hoger PH, Seger RA, Schaad UB, Hitzig WH (1985) Chronic granulomatous disease: uptake and intracellular activity of fosfomycin in granulocytes. Pediatr Res 19:38–44

    PubMed  Google Scholar 

  6. Huizinga TWJ, Van der Schoot CE, Roos D, Weening RS (1991) Induction of neutrophil FC-γ receptor 1 expression can be used as a marker for biologic activity of recombinant interferon-γ in vivo. Blood 77:2088–2090

    PubMed  Google Scholar 

  7. The International Chronic Granulomatous Disease Cooperative Group (1991) A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 324:509–516

    Google Scholar 

  8. Margolis DM, Melwick DA, Alling DW, Gallin JL (1990) Trimethoprim-sulfamethoxazole phrophylaxis in the management of chronic granulomatous disease. J Inf Dis 162:723–726

    Google Scholar 

  9. Mouy R, Fischer A, Vilmer E, Seger R, Grisecelli C (1989) Incidence, severity and prevention of infections in chronic granulomatous disease. J Pediatr 114:555–560

    PubMed  Google Scholar 

  10. Mouy R, Seger R, Bourquin JP, Veber F, Blanche S, Griscelli C, Fischer A (1991) Interferon gamma for chronic granulomatous disease. N Engl J Med 325:1516–1516

    PubMed  Google Scholar 

  11. Muhlebach TJ, Gabay J, Nathan CF, Erny C, Dopfer G, Schroten H, Wahn V, Seger RA (1992). Treatment of patients with chronic granulomatous disease with recombinant human interferon-gamma does not improve neutrophil oxidative metabolism, cytochrome b558 content or levels of four antimicrobial proteins. Clin Exp Immunol 88:203–206

    PubMed  Google Scholar 

  12. Sechler JMG, Malech HL, White CJ, Gallin JL (1988) Recombinant human interferon-g reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. Proc Natl Acad Sci USA 85:4874–4878

    PubMed  Google Scholar 

  13. Segal AW (1989) The electron transport chain of the microbicidal oxidase of phagocytic cells and its involvement in the molecular pathology of chronic granulomatous disease. J Clin Invest 83:1785–1793

    PubMed  Google Scholar 

  14. Seger R, Baumgartner S, Tiefenauer L, Gmunder F (1981) Chronic granulomatous disease: effect of sulfamethoxazole/trimethoprim on neutrophil microbicidal function. Helv Paediatr Acta 36:579–588

    PubMed  Google Scholar 

  15. Weening RS, Kabel P, Pijman P, Roos D (1983) Continuous therapy with sulfamethoxazole-trimethoprim in patients with chronic granulomatous disease. J Pediatr 103:127–130

    PubMed  Google Scholar 

  16. Woodman RC, Erickson RW, Rea J, Jaffe HS, Curnutte JT (1992) Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: evidence against enhanced neutrophil oxidase activity. Blood 79:1558–1562

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fischer, A., Segal, A.W., Seger, R. et al. The management of chronic granulomatous disease. Eur J Pediatr 152, 896–899 (1993). https://doi.org/10.1007/BF01957525

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01957525

Key words

Navigation